Triz 33
30mg
Triz 33 30mg
Research Compound Lyophilized Powder
Metabolic Science

Triz 33

Dual-Receptor Metabolic Agonist

$175.00
Third-Party Lab Tested
COA With Every Order
Fast U.S. Shipping
Text Email

What It Is

A dual-receptor agonist that activates the incretin (GLP-1) and GIP receptors simultaneously. Triz 33 is 33 Degrees' house designation for this dual-receptor research compound (tirzepatide), one of the most extensively studied compounds in modern metabolic research.

How It Works

1
Triz 33 binds the GLP-1 and GIP receptors simultaneously
→
2
GLP-1 pathway reduces appetite signaling and slows gastric emptying
→
3
GIP pathway enhances insulin secretion and influences fat metabolism
→
4
Combined incretin effect studied in glucose-control and body-weight models

What Researchers Study It For

Body weight and composition models
Glycemic control and insulin sensitivity
Appetite and gastric-emptying signaling
Dual-receptor incretin agonism mechanisms

Common Research Protocols

Triz 33 is studied as a subcutaneous injection in the published metabolic research literature. Research protocols are defined within the context of that literature.

Community Interest Areas

The research community has shown strong interest in Triz 33 for its dual-agonist mechanism, which engages both the GLP-1 and GIP incretin pathways at once. This combined incretin activity has generated particular attention in metabolic research circles focused on glucose regulation and body-weight models.

Dual Agonist Simultaneously activates the GLP-1 and GIP incretin receptor pathways
Incretin Science Among the most extensively studied compounds in metabolic research

For research purposes only. Not intended for consumption, clinical application, or diagnostic use.

Research Overview

Endocrine Receptor Research: Retatrutide, Tesamorelin & AOD-9604

How metabolic agonists engage endocrine receptors, what the trial data shows, and common research applications.

Read Article → Safety & Compliance

How Peptide Safety Is Studied

How peptide safety is evaluated in published research — adverse events, regulatory compounding status, source quality, immunogenicity, and the limits of long-term data.

Read Article →
Learn About Peptides